Eli Lilly and Company (NYSE:LLY) Major Shareholder Sells $532,364.52 in Stock

Eli Lilly and Company (NYSE:LLYGet Rating) major shareholder Lilly Endowment Inc sold 1,601 shares of Eli Lilly and stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $332.52, for a total transaction of $532,364.52. Following the sale, the insider now owns 103,964,899 shares of the company’s stock, valued at $34,570,408,215.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Friday, July 15th, Lilly Endowment Inc sold 17,310 shares of Eli Lilly and stock. The shares were sold at an average price of $332.76, for a total transaction of $5,760,075.60.
  • On Wednesday, July 6th, Lilly Endowment Inc sold 177,243 shares of Eli Lilly and stock. The shares were sold at an average price of $330.28, for a total transaction of $58,539,818.04.
  • On Monday, June 27th, Lilly Endowment Inc sold 41,857 shares of Eli Lilly and stock. The shares were sold at an average price of $329.05, for a total transaction of $13,773,045.85.
  • On Friday, June 24th, Lilly Endowment Inc sold 215,000 shares of Eli Lilly and stock. The stock was sold at an average price of $324.31, for a total transaction of $69,726,650.00.
  • On Wednesday, June 22nd, Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock. The stock was sold at an average price of $306.84, for a total transaction of $64,436,400.00.
  • On Friday, May 27th, Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock. The stock was sold at an average price of $318.98, for a total transaction of $63,796,000.00.
  • On Wednesday, May 25th, Lilly Endowment Inc sold 41,610 shares of Eli Lilly and stock. The stock was sold at an average price of $308.95, for a total transaction of $12,855,409.50.
  • On Monday, May 23rd, Lilly Endowment Inc sold 118,856 shares of Eli Lilly and stock. The stock was sold at an average price of $302.73, for a total transaction of $35,981,276.88.
  • On Wednesday, May 18th, Lilly Endowment Inc sold 700 shares of Eli Lilly and stock. The stock was sold at an average price of $302.00, for a total transaction of $211,400.00.
  • On Monday, May 16th, Lilly Endowment Inc sold 80,761 shares of Eli Lilly and stock. The stock was sold at an average price of $302.53, for a total transaction of $24,432,625.33.

Eli Lilly and Stock Up 0.6 %

Shares of Eli Lilly and stock opened at $330.80 on Friday. The company has a market cap of $314.31 billion, a P/E ratio of 49.01, a PEG ratio of 2.35 and a beta of 0.37. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27. Eli Lilly and Company has a one year low of $220.20 and a one year high of $335.33. The firm has a fifty day moving average of $315.23 and a two-hundred day moving average of $286.29.

Eli Lilly and (NYSE:LLYGet Rating) last announced its quarterly earnings results on Thursday, April 28th. The company reported $2.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.32 by $0.30. The business had revenue of $7.81 billion during the quarter, compared to the consensus estimate of $7.29 billion. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. The business’s revenue was up 14.8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.87 EPS. On average, analysts forecast that Eli Lilly and Company will post 8.31 earnings per share for the current year.

Eli Lilly and Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Monday, August 15th will be issued a $0.98 dividend. The ex-dividend date of this dividend is Friday, August 12th. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.19%. Eli Lilly and’s dividend payout ratio is presently 58.07%.

Hedge Funds Weigh In On Eli Lilly and

A number of large investors have recently made changes to their positions in LLY. Cordant Inc. purchased a new position in shares of Eli Lilly and in the 1st quarter valued at about $25,000. AllSquare Wealth Management LLC purchased a new position in Eli Lilly and during the 4th quarter valued at about $28,000. HWG Holdings LP purchased a new position in Eli Lilly and during the 4th quarter valued at about $28,000. Icapital Wealth LLC purchased a new position in Eli Lilly and during the 1st quarter valued at about $28,000. Finally, Leverty Financial Group LLC purchased a new position in Eli Lilly and during the 4th quarter valued at about $29,000. Hedge funds and other institutional investors own 82.75% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on LLY. UBS Group boosted their price target on shares of Eli Lilly and to $335.00 and gave the stock an “outperform” rating in a report on Wednesday. Morgan Stanley boosted their price target on shares of Eli Lilly and from $369.00 to $395.00 and gave the stock an “overweight” rating in a report on Friday, July 8th. Barclays boosted their price target on shares of Eli Lilly and from $333.00 to $355.00 and gave the stock an “overweight” rating in a report on Thursday, July 7th. SVB Leerink began coverage on shares of Eli Lilly and in a report on Monday, May 23rd. They set an “outperform” rating and a $341.00 price target for the company. Finally, Mizuho boosted their price target on shares of Eli Lilly and from $315.00 to $356.00 in a report on Monday, May 2nd. Three investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $316.06.

About Eli Lilly and

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

Insider Buying and Selling by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.